Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
| Condition |
|---|
|
Pancreatic Cancer |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence |
Approximately 1 tablespoon of blood will be collected from each subject.
| Enrollment: | 0 |
| Study Start Date: | October 2012 |
| Study Completion Date: | February 2013 |
| Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
pancreatic cancer
This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
|
Detailed Description:
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients will be recruited from the University of Kansas Cancer Center prior to any treatment for their pancreatic cancer. Final histology and staging will be recorded and correlated with protease concnentration. Healthy subjects will be recruited from the University of Kansas and Kansas State community.
Inclusion Criteria:
Inclusion Criteria for Pancreatic Cancer Patients:
- Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis.
- Patients will have had no prior treatment or surgery
Inclusion Criteria for Healthy Subjects:
- Subjects will have no prior history of any cancer
Exclusion Criteria:
Exclusion Criteria for Pancreatic Cancer Patients
- Any prior treatment for pancreatic cancer
- Poorly controlled diabetes
Exclusion Criteria for Healthy Subjects
- Poorly controlled diabetes
Contacts and Locations More Information
No publications provided
| Responsible Party: | University of Kansas |
| ClinicalTrials.gov Identifier: | NCT01707758 History of Changes |
| Other Study ID Numbers: | 13421 |
| Study First Received: | October 12, 2012 |
| Last Updated: | May 15, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Kansas:
|
pancreatic cancer nanoparticle proteases cell survival |
tumor progression angiogenesis tissue remodeling/invasion |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013